Change in HER2 status during breast tumor progression

Cancer Biomarkers

Volumn 12, Issue 6, 2012, Pages 251-255

  Niikura, Naoki ^a   Ueno, Naoto T ^b  

^a TOKAI UNIVERSITY   (Japan)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

biomarker; Breast neoplasms; HER 2 neu

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; LAPATINIB; PROGESTERONE RECEPTOR; TRASTUZUMAB;

ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GRADING; CANCER GROWTH; CANCER LOCALIZATION; CANCER RECURRENCE; CANCER SIZE; CANCER SURVIVAL; DISTANT METASTASIS; FEMALE; FINE NEEDLE ASPIRATION BIOPSY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE DOSAGE; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; META ANALYSIS (TOPIC); MULTIMODALITY CANCER THERAPY; OVERALL SURVIVAL; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; SYSTEMIC THERAPY; TUMOR BIOPSY;

BREAST NEOPLASMS; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; PROGNOSIS; RECEPTOR, ERBB-2; TUMOR MARKERS, BIOLOGICAL;

EID: 84878925004     PISSN: 15740153     EISSN: 18758592     Source Type: Journal    
DOI: 10.3233/CBM-130313     Document Type: Article

References (44)

1. Sauter G, Lee J, Bartlett JM, et al: Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. J Clin Oncol 27: 1323-33, 2009.
2. Slamon DJ, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783-92, 2001.
3. Masood S, Bui MM: Assessment of Her-2/neu overexpression in primary breast cancers and their metastatic lesions: an immunohistochemical study. Ann Clin Lab Sci 30: 259-65, 2000.
4. Shimizu C, Fukutomi T, Tsuda H, et al: c-erbB-2 protein overexpression and p53 immunoreaction in primary and recurrent breast cancer tissues. J Surg Oncol 73: 17-20, 2000.
5. Simon R, Nocito A, Hubscher T, et al: Patterns of her-2/neu amplification and overexpression in primary and metastatic breast cancer. J Natl Cancer Inst 93: 1141-6, 2001.
6. Tanner M, Jarvinen P, Isola J: Amplification of HER-2/neu and topoisomerase IIalpha in primary and metastatic breast cancer. Cancer Res 61: 5345-8, 2001.
7. Gancberg D, Di Leo A, Cardoso F, et al: Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites. Ann Oncol 13: 1036-43, 2002.
8. Xu R, Perle MA, Inghirami G, et al: Amplification of Her-2/neu gene in Her-2/neu-overexpressing and-nonexpressing breast carcinomas and their synchronous benign, premalignant, and metastatic lesions detected by FISH in archival material. Mod Pathol 15: 116-24, 2002.
9. Taucher S, Rudas M, Mader RM, et al: Influence of neoadjuvant therapy with epirubicin and docetaxel on the expression of HER2/neu in patients with breast cancer. Breast Cancer Res Treat 82: 207-13, 2003.
10. Carlsson J, Nordgren H, Sjostrom J, et al: HER2 expression in breast cancer primary tumours and corresponding metastases. Original data and literature review. Br J Cancer 90: 2344-8, 2004.
11. Regitnig P, Schippinger W, Lindbauer M, et al: Change of HER-2/neu status in a subset of distant metastases from breast carcinomas. J Pathol 203: 918-26, 2004.
12. Zidan J, Dashkovsky I, Stayerman C, et al: Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease. Br J Cancer 93: 552-6, 2005.
13. Gong Y, Booser DJ, Sneige N: Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma. Cancer 103: 1763-9, 2005.
14. Pectasides D, Gaglia A, Arapantoni-Dadioti P, et al: HER-2/neu status of primary breast cancer and corresponding metastatic sites in patients with advanced breast cancer treated with trastuzumab-based therapy. Anticancer Res 26: 647-53, 2006.
15. D'Andrea MR, Limiti MR, Bari M, et al: Correlation between genetic and biological aspects in primary non-metastatic breast cancers and corresponding synchronous axillary lymph node metastasis. Breast Cancer Res Treat 101: 279-84, 2007.
16. Simmons C, Miller N, Geddie W, et al: Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases? Ann Oncol 20: 1499-504, 2009.
17. Thompson AM, Jordan LB, Quinlan P, et al: Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: the Breast Recurrence In Tissues Study (BRITS). Breast Cancer Res 12: R92, 2010.
18. Wilking U, Karlsson E, Skoog L, et al: HER2 status in a population-derived breast cancer cohort: discordances during tumor progression. Breast Cancer Research and Treatment 125: 553-561, 2010.
19. Lower EE, Glass E, Blau R, et al: HER-2/neu expression in primary and metastatic breast cancer. Breast Cancer Research and Treatment 113: 301-306, 2008.
20. Burstein HJ, Harris LN, Gelman R, et al: Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/ cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study. J Clin Oncol 21: 46-53, 2003.
21. Harris LN, You F, Schnitt SJ, et al: Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer. Clin Cancer Res 13: 1198-207, 2007.
22. Hurley J, Doliny P, Reis I, et al: Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer. Journal of Clinical Oncology 24: 1831-1838, 2006.
23. Mittendorf EA, Wu Y, Scaltriti M, et al: Loss of HER2 Amplification Following Trastuzumab-Based Neoadjuvant Systemic Therapy and Survival Outcomes. Clin Cancer Res 15: 7381-8, 2009.
24. Khasraw M, Brogi E, Seidman AD: The need to examine metastatic tissue at the time of progression of breast cancer: is re-biopsy a necessity or a luxury? Curr Oncol Rep 13: 17-25, 2011.
25. Niikura N, Liu J, Hayashi N, et al: Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors. J Clin Oncol 30: 593-599, 2012.
26. Ding L, Ellis MJ, Li S, et al: Genome remodelling in a basallike breast cancer metastasis and xenograft. Nature 464: 999-1005, 2010.
27. Houssami N, Macaskill P, Balleine RL, et al: HER2 discordance between primary breast cancer and its paired metastasis: tumor biology or test artefact? Insights through metaanalysis. Breast Cancer Res Treat 129: 659-674, 2011.
28. Thompson AM, Jordan LB, Quinlan P, et al: Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: the Breast Recurrence In Tissues Study (BRITS). Breast Cancer Res 12: R92, 2010.
29. Amir E, Miller N, Geddie W, et al: Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer. J Clin Oncol 30: 587-592, 2012.
30. Hurley J, Doliny P, Reis I, et al: Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer. J Clin Oncol 24: 1831-1838, 2006.
31. Liedtke C, Broglio K, Moulder S, et al: Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer. Ann Oncol 20: 1953-1958, 2009.
32. Lindstrom LS, Karlsson E,Wilking UM, et al: Clinically Used Breast Cancer Markers Such as Estrogen Receptor, Progesterone Receptor, and Human Epidermal Growth Factor Receptor 2 Are Unstable Throughout Tumor Progression. J Clin Oncol, 2012.
33. Amir E, Clemons M, Purdie CA, et al: Tissue confirmation of disease recurrence in breast cancer patients: pooled analysis of multi-centre, multi-disciplinary prospective studies. Cancer Treat Rev 38: 708-714, 2012.
34. Hopper KD, Abendroth CS, Sturtz KW, et al: Blinded comparison of biopsy needles and automated devices in vitro: 2. Biopsy of medical renal disease. AJR Am J Roentgenol 161: 1299-301, 1993.
35. Hopper KD, Abendroth CS, Sturtz KW, et al: Blinded comparison of biopsy needles and automated devices in vitro: 1. Biopsy of diffuse hepatic disease. AJR Am J Roentgenol 161: 1293-7, 1993.
36. Charboneau JW, Reading CC, Welch TJ: CT and sonographically guided needle biopsy: current techniques and new innovations. AJR Am J Roentgenol 154: 1-10, 1990.
37. Reading CC, Charboneau JW, James EM, et al: Sonographically guided percutaneous biopsy of small (3 cm or less) masses. AJR Am J Roentgenol 151: 189-92, 1988.
38. Hudock JA, Hanau CA, Christen R, et al: Expression of estrogen and progesterone receptors in cytologic specimens using various fixatives. Diagn Cytopathol 15: 78-83, 1996.
39. Hanley KZ, Siddiqui MT, Lawson D, et al: Evaluation of new monoclonal antibodies in detection of estrogen receptor, progesterone receptor, and Her2 protein expression in breast carcinoma cell block sections using conventional microscopy and quantitative image analysis. Diagn Cytopathol 37: 251-7, 2009.
40. Yaziji H, Goldstein LC, Barry TS, et al: HER-2 testing in breast cancer using parallel tissue-based methods. JAMA 291: 1972-1977, 2004.
41. Wolff AC, Hammond ME, Schwartz JN, et al: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25: 118-45, 2007.
42. Clinical Trial.gov. http://clinicaltrials.gov/ct2/show/NCT0127 5677?term=National+Surgical+Adjuvant+Breast+and+Bowel +Project+trastuzumab& rank=3.
43. Baselga J, Cortes J, Kim SB, et al: Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 366: 109-119, 2012.
44. Krop IE, Lorusso P, Miller KD, et al: A Phase II Study of Trastuzumab Emtansine in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Who Were Previously Treated With Trastuzumab, Lapatinib, an Anthracycline, a Taxane, and Capecitabine. J Clin Oncol 30: 3234-3241, 2012.